Raúl Recio

Dr. Raúl Recio

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
RRRaúl Recio
Raúl Recio
JVJennifer Villa
Jennifer Villa
EVEsther Viedma
Esther Viedma
MOMaría Ángeles Orellana
María Ángeles Orellana
JLJaime Lora-Tamayo
Jaime Lora-Tamayo
FCFernando Chaves
Fernando Chaves

1 December 2021 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
RRRaúl Recio
Raúl Recio
EVEsther Viedma
Esther Viedma
SGSara González-Bodí
Sara González-Bodí
JVJennifer Villa
Jennifer Villa
MOMaría Ángeles Orellana
María Ángeles Orellana
FCFernando Chaves
Fernando Chaves

10 December 2019 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
RRRaúl Recio
Raúl Recio
ISIrina Sánchez-Diener
Irina Sánchez-Diener
EVEsther Viedma
Esther Viedma
MMMaría Ángeles Meléndez-Carmona
María Ángeles Meléndez-Carmona
JVJennifer Villa
Jennifer Villa
AOAntonio Oliver
Antonio Oliver

1 May 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
RRRaúl Recio
Raúl Recio
MMM.á. Meléndez-Carmona
M.á. Meléndez-Carmona
MMM.C. Martín-Higuera
M.C. Martín-Higuera
VPV. Pérez
V. Pérez
ELE. López
E. López
APA. Pérez-Ayala
A. Pérez-Ayala

4 July 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MRMarta Rolo
Marta Rolo
MMMaría Carmen Martín-Higuera
María Carmen Martín-Higuera
EVEsther Viedma
Esther Viedma
JVJennifer Villa
Jennifer Villa
MMMikel Mancheño-Losa
Mikel Mancheño-Losa
RRRaúl Recio
Raúl Recio
To investigate the impact of the time-to-positivity of blood cultures (TTP) on 30-day mortality in patients with Pseudomonas aeruginosa bacteremia. All nonduplicated episodes of P. aeruginosa monomicrobial bacteremia in adult patients from January 2013 to February 2020 were analysed. Epidemiological and clinical data were collected. TTP of blood cultures for P. aeruginosa isolates was automatically recorded. Multivariate analysis identified factors predicting 30-day overall mortality. A total of 328 patients were identified. The median TTP for P. aeruginosa isolates was 15 h (interquartile range [IQR] 12-18 h). All multidrug-resistant and extensively drug-resistant (MDR/XDR) episodes were positive within the first 36 h. The 30-day mortality rate was 32.3%. The best cut-off value of the TTP for predicting mortality was 16 h (area under the receiver operating characteristic curve 0.62, 95% confidence interval [CI] 0.56-0.67, P = 0.001). The 30-day mortality rate was significantly higher in the TTP ≤16 h group (41.0% vs. 19.5%, P < 0.001). In a multivariate analysis, severe neutropenia (adjusted odds ratio [aOR] 2.67, 95% CI 1.4-5.09, P = 0.002), septic shock (aOR 3.21, 95% CI 1.57-5.89, P < 0.001), respiratory source (aOR 4.37, 95% CI 2.24-8.52, P < 0.001), nosocomial acquisition (aOR 1.99, 95% CI 1.06-3.71, P = 0.030), TTP ≤16 h (aOR 2.27, 95% CI 2.12-4.25, P = 0.010), and MDR/XDR phenotype (aOR 2.54, 95% CI 1.38-4.67, P = 0.002) were independently associated with 30-day mortality. A short TTP (≤16 h) was independently associated with increased 30-day mortality. After local validation, this routinely available microbiological parameter might be useful for guiding empirical antipseudomonal therapies and supporting the close monitoring of patients with P. aeruginosa bacteremia.

30 July 2024 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
MMMari Cruz Martín-Delgado
Mari Cruz Martín-Delgado
PRPilar de Lucas Ramos
Pilar de Lucas Ramos
AGAlejandra García-Botella
Alejandra García-Botella
RCRafael Canton
Rafael Canton
Alberto García-LledoAlberto García-Lledo
Alberto García-Lledo
EBEmilio Bouza
Emilio Bouza
Group A ß-hemolytic Streptococcus (S. pyogenes), also known as GAS, is a Gram-positive bacterium. It can be easily identified in the microbiology laboratory by its ability to hemolyse blood in culture media. This bacterium is highly virulent due to its production of enzymes and toxins, and its ability to cause immunologically mediated diseases such as rheumatic fever and post-streptococcal glomerulonephritis. GAS is the primary cause of bacterial pharyngotonsillitis, although it is typically a benign and non-invasive disease. However, it also has the potential to cause severe skin and soft tissue infections, necrotising fasciitis, bacteraemia and endocarditis, pneumonia and empyema, and streptococcal toxic shock syndrome, without any age or predisposition limits. The term invasive GAS disease (iGAS) is used to refer to this group of conditions. In more developed countries, iGAS disease has declined thanks to improved hygiene and the availability of antibiotics. For example, rheumatic fever has practically disappeared in countries such as Spain. However, recent data suggests a potential increase in some iGAS diseases, although the accuracy of this data is not consistent. Because of this, the COVID and Emerging Pathogens Committee of the Illustrious Official College of Physicians of Madrid (ICOMEM) has posed several questions about invasive GAS infection, especially its current situation in Spain. The committee has enlisted the help of several experts in the field to answer these questions. The following lines contain the answers that we have collaboratively produced, aiming to assist not only the members of ICOMEM but also anyone interested in this topic.